Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Surgical ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Howlader N. Noone A.M. Krapcho M. SEER Cancer Statistics Review, 1975–2016. National Cancer Institute, Bethesda (MD)2019
- Global Cancer Facts & Figures 4th Edition.American Cancer Society, Atlanta (GA)2018
- The epidemic of oesophageal carcinoma: where are we now?.Cancer Epidemiol. 2016; 41: 88-95
- Proliferative activity of cancer cells in front and center areas of carcinoma in situ and invasive sites of esophageal squamous-cell carcinoma.Int J Cancer. 1998; 78: 149-152
- Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma.J Natl Cancer Inst. 1996; 88: 1222-1227
- Esophageal cancer: risk factors, screening and endoscopic treatment in Western and Eastern countries.World J Gastroenterol. 2015; 21: 7933-7943
- Epidemiology of esophageal cancer.Surg Clin North Am. 2012; 92: 1077-1087
- Meat consumption and risk of esophageal and gastric cancer in a large prospective study.Am J Gastroenterol. 2011; 106: 432-442
- Prospective study of serum selenium levels and incident esophageal and gastric cancers.J Natl Cancer Inst. 2000; 92: 1753-1763
- Zinc concentration in esophageal biopsy specimens measured by x-ray fluorescence and esophageal cancer risk.J Natl Cancer Inst. 2005; 97: 301-306
- The concise handbook of family cancer syndromes. Mayo Familial Cancer Program.J Natl Cancer Inst. 1998; 90: 1039-1071
- Concise handbook of familial cancer susceptibility syndromes - second edition.J Natl Cancer Inst Monogr. 2008; : 1-93
- Molecular genetics of Bloom's syndrome.Hum Mol Genet. 1996; 5 Spec No: 1457-1463
- Epidemiologic differences in esophageal cancer between Asian and Western populations.Chin J Cancer. 2012; 31: 281-286
- The Male Predominance in Esophageal Adenocarcinoma.Clin Gastroenterol Hepatol. 2016; 14: 338-347 e331
- Surgical pathology of adenocarcinoma arising in Barrett's esophagus. Analysis of 67 cases.Am J Surg Pathol. 1995; 19: 183-191
- Carcinoma of the esophagus. Prognostic significance of histologic type.J Thorac Cardiovasc Surg. 1995; 109 ([discussion: 139]): 130-138
- Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux.Aliment Pharmacol Ther. 2010; 32: 1222-1227
- Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology.Am J Gastroenterol. 1998; 93: 1028-1032
- Barrett's oesophagus diagnostic criteria: endoscopy and histology.Best Pract Res Clin Gastroenterol. 2015; 29: 77-96
- Incidence of adenocarcinoma among patients with Barrett's esophagus.N Engl J Med. 2011; 365: 1375-1383
- Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis.Gastrointest Endosc. 2008; 67: 394-398
- Barrett's esophagus.N Engl J Med. 2014; 371: 836-845
- Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated.Am J Gastroenterol. 2010; 105: 1523-1530
- Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus.Gastroenterology. 2011; 141 (1186.e1): 1179-1186
- Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium.J Natl Cancer Inst. 2010; 102: 1344-1353
- A meta-analysis on alcohol drinking and esophageal and gastric cardia adenocarcinoma risk.Ann Oncol. 2012; 23: 287-297
- A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma.Ann Oncol. 2013; 24: 609-617
- Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis.Gastroenterology. 2012; 142 ([quiz: e422–3]): 442-452.e5
- A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome.Clin Cancer Res. 2008; 14: 3216-3222
- A segregation analysis of Barrett's esophagus and associated adenocarcinomas.Cancer Epidemiol Biomarkers Prev. 2010; 19: 666-674
- Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia.J Natl Cancer Inst. 2004; 96: 388-396
- Helicobacter pylori infection, reflux esophagitis, and atrophic gastritis: an unexplored triangle.Am J Gastroenterol. 1998; 93: 394-400
- Gastrointestinal bleeding due to gastrointestinal tract malignancy: natural history, management, and outcomes.Dig Dis Sci. 2017; 62: 491-501
- Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography.Clin Nucl Med. 2000; 25: 882-887
- Clinical efficacy and failure pattern in patients with cervical esophageal cancer treated with definitive chemoradiotherapy.Radiother Oncol. 2015; 116: 257-261
- Surveillance of Barrett's esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study.Am J Gastroenterol. 2014; 109: 1215-1222
- Epidemiology, diagnosis, and management of esophageal adenocarcinoma.Gastroenterology. 2015; 149: 302-317 e301
- ACG clinical guideline: diagnosis and management of Barrett's esophagus.Am J Gastroenterol. 2016; 111 ([quiz: 51]): 30-50
- Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis.Gastrointest Endosc. 2012; 75: 242-253
- Do we still need EUS in the workup of patients with early esophageal neoplasia? A retrospective analysis of 131 cases.Gastrointest Endosc. 2011; 73: 662-668
- Endosonographic features predictive of lymph node metastasis.Gastrointest Endosc. 1994; 40: 442-446
- Helical CT versus EUS with fine needle aspiration for celiac nodal assessment in patients with esophageal cancer.Gastrointest Endosc. 2002; 55: 648-654
- Positron emission tomography with F-18-fluorodeoxyglucose in a combined staging strategy of esophageal cancer prevents unnecessary surgical explorations.J Gastrointest Surg. 2005; 9: 54-61
- Improvement in staging of esophageal cancer with the addition of positron emission tomography.Ann Thorac Surg. 1997; 64 ([discussion: 776–7]): 770-776
- Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy.Cancer. 2007; 109: 125-134
- Role of repeat 18F-fluorodeoxyglucose positron emission tomography examination in predicting pathologic response following neoadjuvant chemoradiotherapy for esophageal adenocarcinoma.JAMA Surg. 2015; 150: 555-562
- [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.Ann Surg. 2009; 250: 888-894
- NCCN Clinical Practice Guidelines in Oncology.(Available at:) (Accessed September 1, 2019)
- The cost effectiveness of radiofrequency ablation for Barrett's esophagus.Gastroenterology. 2012; 143: 567-575
- Barrett's esophagus: the role of laparoscopic fundoplication.Ann Thorac Surg. 2004; 77: 393-396
- Barrett's esophagus.J Gastrointest Surg. 2004; 8: 1-17
- Endoscopic surveillance of columnar-lined esophagus: frequency of intestinal metaplasia detection and impact of antireflux surgery.Ann Surg. 2001; 234: 619-626
- Guidelines for clinical and pathologic studies on carcinoma of the esophagus, ninth edition: Preface, general principles, part I.Esophagus. 2004; 1: 61-88
- Prediction of lymph node status in superficial esophageal carcinoma.Ann Surg Oncol. 2008; 15: 3278-3288
- Prognostic impact of upper, middle, and lower third mucosal or submucosal infiltration in early esophageal cancer.Ann Surg. 2011; 254 ([discussion: 807–8]): 802-807
- Prediction of lymph node status in patients with superficial esophageal carcinoma: analysis of 160 surgically resected cancers.Am J Surg. 2006; 191: 250-254
- Histopathological criteria for additional treatment after endoscopic mucosal resection for esophageal cancer: analysis of 464 surgically resected cases.Mod Pathol. 2006; 19: 475-480
- The overall prevalence of metastasis in T1 esophageal squamous cell carcinoma: a retrospective analysis of 295 patients.Ann Surg. 2013; 257: 1032-1038
- Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers.Ann Surg. 2011; 254: 67-72
- A comparison of endoscopic treatment and surgery in early esophageal cancer: an analysis of surveillance epidemiology and end results data.Am J Gastroenterol. 2008; 103: 1340-1345
- Results of radiation therapy for superficial esophageal cancer using the standard radiotherapy method recommended by the Japanese Society of Therapeutic Radiology and Oncology (JASTRO) Study Group.Anticancer Res. 2006; 26: 1507-1512
- High dose rate brachytherapy for superficial cancer of the esophagus.Int J Radiat Oncol Biol Phys. 2000; 46: 71-76
- Superficial esophageal cancer: multicenter analysis of results of definitive radiation therapy in Japan.Radiology. 1995; 196: 271-274
- Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy.J Thorac Cardiovasc Surg. 2002; 123: 175-183
- Cardia cancer: attempt at a therapeutically relevant classification.Chirurg. 1987; 58 ([in German]): 25-32
- Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials.Int J Surg. 2018; 51: 120-127
- Preoperative chemoradiotherapy for esophageal or junctional cancer.N Engl J Med. 2012; 366: 2074-2084
- Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer.Am J Clin Oncol. 2010; 33: 346-352
- S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma.J Clin Oncol. 2011; 29: 4555-4560
- Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.J Clin Oncol. 2008; 26: 1086-1092
- A single institution experience with neoadjuvant chemoradiation (CRT) with irinotecan (I) and cisplatin (C) in locally advanced esophageal carcinoma (LAEC).J Clin Oncol. 2009; 27: e15619
- Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response.J Clin Oncol. 2006; 24: 3953-3958
- Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.J Clin Oncol. 2012; 30: 2327-2333
- Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.N Engl J Med. 2001; 345: 725-730
- Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction.J Thorac Oncol. 2009; 4: 1264-1269
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.Lancet. 2010; 376: 687-697
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.Lancet. 2014; 383: 31-39
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.Lancet Oncol. 2014; 15: 1224-1235
- Clinical tools do not predict pathological complete response in patients with esophageal squamous cell cancer treated with definitive chemoradiotherapy.Dis Esophagus. 2014; 27: 355-359
- Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma.J Thorac Cardiovasc Surg. 2018; 155: 2710-2721.e3
- Optimum lymphadenectomy for esophageal cancer.Ann Surg. 2010; 251: 46-50
- Transhiatal esophagectomy: clinical experience and refinements.Ann Surg. 1999; 230 ([discussion: 400–3]): 392-400
- A comprehensive review of anastomotic technique in 432 esophagectomies.Ann Thorac Surg. 2013; 95 ([discussion 1160–1]): 1154-1160
- Left thoracoabdominal esophagogastrectomy: still a valid operation for carcinoma of the distal esophagus and esophagogastric junction.Dis Esophagus. 2006; 19: 340-345
- Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial.Lancet. 2012; 379: 1887-1892
Article info
Publication history
Published online: April 11, 2020
Identification
Copyright
© 2020 Elsevier Inc. All rights reserved.
